Qiagen N.V. $QGEN Stake Lessened by Moors & Cabot Inc.

Moors & Cabot Inc. lessened its holdings in Qiagen N.V. (NYSE:QGEN) by 6.3% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 330,748 shares of the company’s stock after selling 22,061 shares during the period. Moors & Cabot Inc. owned about 0.16% of Qiagen worth $14,874,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also modified their holdings of the business. Lingohr Asset Management GmbH purchased a new position in shares of Qiagen during the 3rd quarter valued at $4,218,000. Allianz Asset Management GmbH boosted its position in Qiagen by 53.7% during the third quarter. Allianz Asset Management GmbH now owns 1,529,224 shares of the company’s stock valued at $68,028,000 after purchasing an additional 534,527 shares during the last quarter. Retirement Systems of Alabama purchased a new position in Qiagen in the third quarter valued at about $2,868,000. Barclays PLC grew its stake in Qiagen by 14.3% in the third quarter. Barclays PLC now owns 1,086,931 shares of the company’s stock valued at $48,564,000 after purchasing an additional 135,638 shares in the last quarter. Finally, Great Lakes Advisors LLC bought a new stake in shares of Qiagen in the 3rd quarter valued at approximately $3,677,000. Hedge funds and other institutional investors own 70.00% of the company’s stock.

Qiagen Price Performance

Shares of Qiagen stock opened at $36.65 on Friday. The company has a current ratio of 3.21, a quick ratio of 2.57 and a debt-to-equity ratio of 0.49. The firm has a fifty day simple moving average of $37.76 and a 200-day simple moving average of $44.80. The stock has a market capitalization of $7.55 billion, a price-to-earnings ratio of 19.14, a PEG ratio of 3.59 and a beta of 0.64. Qiagen N.V. has a 1-year low of $32.53 and a 1-year high of $57.81.

Qiagen (NYSE:QGEN) last posted its earnings results on Thursday, May 7th. The company reported $0.54 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $0.54. The business had revenue of $492.32 million for the quarter, compared to analyst estimates of $496.15 million. Qiagen had a net margin of 19.16% and a return on equity of 14.40%. During the same period last year, the business posted $0.56 EPS. On average, sell-side analysts expect that Qiagen N.V. will post 2.43 earnings per share for the current year.

Qiagen Increases Dividend

The firm also recently disclosed an annual dividend, which will be paid on Tuesday, July 14th. Investors of record on Tuesday, July 7th will be given a dividend of $0.35 per share. The ex-dividend date of this dividend is Tuesday, July 7th. This represents a dividend yield of 104.0%. This is a boost from Qiagen’s previous annual dividend of $0.26. Qiagen’s payout ratio is presently 13.61%.

Trending Headlines about Qiagen

Here are the key news stories impacting Qiagen this week:

• Positive Sentiment: QIAGEN announced two custom RUO digital PCR assays to support research and surveillance efforts tied to the Bundibugyo ebolavirus outbreak, reinforcing demand for its QIAcuity digital PCR platform and its role in infectious-disease monitoring. Article Title
• Positive Sentiment: A Zacks commentary pointed to longer-term growth drivers for QIAGEN, including new product launches, automation via Connect, and expansion of the QIAstat-Dx menu, suggesting the company is working to stabilize growth through 2027. Article Title
• Neutral Sentiment: Qiagen’s second-quarter and multi-year earnings estimates were trimmed by Zacks Research, but the firm kept a Hold rating and still sees earnings growth over the next several years. Article Title
• Neutral Sentiment: Pomerantz LLP said it is investigating claims on behalf of Qiagen investors, which adds legal uncertainty but does not yet indicate a formal lawsuit or financial impact. Article Title
• Negative Sentiment: Multiple Zacks Research updates lowered earnings forecasts for FY2026, FY2027, FY2028 and several quarterly periods, signaling some concern about near-term profitability and tempering enthusiasm for the stock. Article Title

Analysts Set New Price Targets

A number of equities analysts recently commented on QGEN shares. TD Cowen restated a “hold” rating and issued a $40.00 price objective (down from $46.00) on shares of Qiagen in a report on Thursday, May 7th. Weiss Ratings lowered shares of Qiagen from a “hold (c)” rating to a “hold (c-)” rating in a research note on Tuesday, May 12th. Robert W. Baird set a $43.00 price target on shares of Qiagen and gave the company an “outperform” rating in a report on Wednesday, April 29th. Stifel Nicolaus set a $36.00 price objective on shares of Qiagen and gave the company a “hold” rating in a research note on Monday, May 18th. Finally, Zacks Research upgraded shares of Qiagen from a “strong sell” rating to a “hold” rating in a report on Wednesday, April 29th. One analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating and seven have issued a Hold rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $44.98.

About Qiagen

Qiagen NV (NYSE: QGEN) is a global provider of sample and assay technologies designed to enable molecular testing in the fields of molecular diagnostics, applied testing, academic research and pharmaceutical development. The company’s solutions span the full workflow of nucleic acid and protein analysis, offering customers standardized kits, instruments and software tools that streamline the preparation, detection and quantification of DNA, RNA and proteins.

The company’s product portfolio includes nucleic acid extraction and purification systems, polymerase chain reaction (PCR) reagents and instrumentation, digital PCR platforms, next-generation sequencing (NGS) library‐preparation kits and proteomics solutions.